 |
|
|
 |
NAOKI IWAMOTO, ATSUSHI KAWAKAMI, MAMI TAMAI, KEITA FUJIKAWA, KAZUHIKO ARIMA, TOSHIYUKI ARAMAKI, SHINYA KAWASHIRI, KUNIHIRO ICHINOSE, MAKOTO KAMACHI, HIDEKI NAKAMURA, TOMOKI ORIGUCHI, HIROAKI IDA, and KATSUMI EGUCHI ABSTRACT. Objective. To investigate whether anticyclic citrullinated peptide antibodies (anti-CCP) predict the subset of Japanese patients with Sjögren’s syndrome (SS) with articular manifestations. Methods. Eighty-seven patients with SS were enrolled. Prevalence of anti-CCP antibodies, IgM rheumatoid factor, anti-Ro/SSA antibody, anti-La/SSB antibody, and serum IgG concentration and their relation to articular manifestations were examined. Articular manifestations included morning stiffness and the presence of tender or swollen joints. Results. Eighty-seven SS patients were divided into 3 groups: 14 secondary SS with nonerosive rheumatoid arthritis (RA); 47 primary SS with articular manifestations; and 26 primary SS without articular manifestations. Ten out of 14 secondary SS with nonerosive RA expressed anti-CCP. Anti-CCP was the only statistically proven marker preferentially distributed in patients with articular manifestations (the first 2 groups) compared to primary SS without such manifestations; however, its frequency was low in primary SS. No patient with primary SS without articular manifestations expressed anti-CCP. Conclusion. Anti-CCP is found in the subset of Japanese with SS with articular manifestations although most of those with anti-CCP-positive SS were classified as secondary SS with RA. (First Release Dec 15 2008; doi 10.3899/jrheum.080193) Key Indexing Terms: SJÖGREN’S SYNDROME ARTICULAR MANIFESTATIONS ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES From the Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University; and Nagasaki University School of Health Sciences, Nagasaki University, Nagasaki, Japan. Supported by a grant from The Ministry of Health, Labour and Welfare, Japan. N. Iwamoto, MD; A. Kawakami, MD; M. Tamai, MD; K. Fujikawa, MD; K. Arima, MD; T. Aramaki, MD; S. Kawashiri, MD; K. Ichinose, MD; M. Kamachi, MD; H. Nakamura, MD, Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University; T. Origuchi, MD, Nagasaki University School of Health Sciences; H. Ida, MD; K. Eguchi, MD, PhD, Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University. Address reprint requests to Prof. K. Eguchi, Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. E-mail: eguchi@net.nagasaki-u.ac.jp Accepted for publication August 8, 2008. |
